Literature DB >> 20574710

Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell.

Xian-Run Luo1, Jian-Sheng Li, Ying Niu, Li Miao.   

Abstract

Suicide genes such as cytosine deaminase (CD) and herpes simplex virus thymidine kinase (TK) encode products that convert nontoxic substances (prodrugs) into toxic metabolites. Studies in recent years indicated that survivin(sur) expression was associated with the biological behaviors of gastric carcinoma. In the present study, targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell were investigated, the recombinant pSCT vector containing CD and TK genes driven by sur promoter was constructed and transfected into SGC-7901 cells. After adding the CCV and 5-FC, the effects of double suicide genes on cell growth, cell cycle and proliferation were determined by MTT assay and flow cytometry (FCM). The results showed that sur promoter could specifically drive the expression of double CD/TK gene in SGC-7901 cells, whereas not in the normal GES-1 cell. After using CCV and 5-FC, the growth of SGC-7901 cells was inhibited. G1 phase proportion was significantly higher in SGC-7901 cells transfected with double suicide genes than the untransfected cells. These results suggest that CD and TK double suicide genes driven by sur promoter could provide a new approach for enhancing selective suicide gene therapy of CD/5-FC for the treatment of advanced gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574710     DOI: 10.1007/s11033-010-0218-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

Review 1.  Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm.

Authors:  Dario C Altieri
Journal:  J Cell Biochem       Date:  2004-07-01       Impact factor: 4.429

2.  Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.

Authors:  Yan Li; Dong-lan Sun; Ya-nan Duan; Xiao-juan Zhang; Na Wang; Rong-miao Zhou; Zhi-feng Chen; Shi-jie Wang
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

3.  Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.

Authors:  Erkan Topuz; Mert Basaran; Pinar Saip; Adnan Aydiner; Andac Argon; Burak Sakar; Faruk Tas; Kazim Uygun; Dursun Bugra; N Faruk Aykan
Journal:  Am J Clin Oncol       Date:  2002-12       Impact factor: 2.339

4.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 5.  Multidisciplinary approach to understand the pathogenesis of gastric cancer.

Authors:  Juan Shang; A S Pena
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

6.  Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.

Authors:  Ladan Teimoori-Toolabi; Kayhan Azadmanesh; Amir Amanzadeh; Sirous Zeinali
Journal:  BioDrugs       Date:  2010-04-01       Impact factor: 5.807

Review 7.  Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.

Authors:  Dario C Altieri
Journal:  Mol Cancer Ther       Date:  2006-03       Impact factor: 6.261

8.  Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.

Authors:  H Garg; R Salcedo; G Trinchieri; R Blumenthal
Journal:  Cancer Gene Ther       Date:  2009-10-09       Impact factor: 5.987

9.  Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Lioudmila Kaliberova; Bin Liu; Angel A Rivera; Dirk M Nettelbeck; Parameshwar J Mahasreshti; Charles A Leath; Shannon Barker; Masato Yamaoto; Fengzhi Li; Ronald D Alvarez; David T Curiel
Journal:  Cancer Gene Ther       Date:  2004-04       Impact factor: 5.987

10.  Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.

Authors:  Marion Lanteri; Laurence Ollier; Valérie Giordanengo; Jean-Claude Lefebvre
Journal:  Breast Cancer Res       Date:  2005-05-03       Impact factor: 6.466

View more
  8 in total

1.  Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro.

Authors:  Shuhong Hao; Xiaoyuan Du; Yang Song; Ming Ren; Qiwei Yang; Ao Wang; Qingyu Wang; Haiyue Zhao; Zhenwu Du; Guizhen Zhang
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

2.  Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1α induction.

Authors:  Bin Chen; Sun Yuping; Jian Ni
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

3.  Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma.

Authors:  Jian Niu; Chunyang Xing; Chao Yan; Hao Liu; Yuqiong Cui; Haisheng Peng; Yingli Chen; Dianjun Li; Chuanlu Jiang; Nannan Li; Haicheng Yang
Journal:  Tumour Biol       Date:  2013-07-05

4.  Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma.

Authors:  Gui-Chao Li; Zhen Zhang; Xue-Jun Ma; Wei-Lie Gu; Ya-Nong Wang; Jin Li
Journal:  Mol Biol Rep       Date:  2011-05-11       Impact factor: 2.316

5.  Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use.

Authors:  Kyoung-Yoon Kim; Bo-Rim Yi; Hye-Rim Lee; Nam-Hee Kang; Eui-Bae Jeung; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Oncol       Date:  2011-12-08       Impact factor: 5.650

6.  Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma.

Authors:  Yu Xu; Jinxuan Hou; Zhengchun Liu; Haijun Yu; Wenjie Sun; Jie Xiong; Zhengkai Liao; Fuxiang Zhou; Conghua Xie; Yunfeng Zhou
Journal:  J Transl Med       Date:  2011-04-11       Impact factor: 5.531

7.  Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.

Authors:  Miroslava Matuskova; Zuzana Kozovska; Lenka Toro; Erika Durinikova; Silvia Tyciakova; Zuzana Cierna; Roman Bohovic; Lucia Kucerova
Journal:  J Exp Clin Cancer Res       Date:  2015-04-09

8.  Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct.

Authors:  Feng Ye; Bo Zhong; Guorong Dan; Fan Jiang; Yan Sai; Jiqing Zhao; Huiqin Sun; Zhongmin Zou
Journal:  Arch Med Sci       Date:  2013-05-28       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.